Neurocrine Biosciences Delivers Strong Q3 on Vykat Rebound, RBC Says

11:39 AM EST, 11/03/2026 (MT Newswires) -- Neurocrine Biosciences (NBIX) delivered strong Q3 results, driven by continued demand across its core legacy products and a recovery in Vykat, RBC Capital Markets said in a note Monday. The analysts said the strong commercial execution could help improve investor sentiment and narrow the gap between the company's valuation and its underlying fundamentals ahead of several pipeline readouts in 2027. The analysts said Vykat's revenue of $107 million beat both their estimates and Wall Street's, which were in the low-to-mid-$90 million range. The rebound was mainly driven by new patient demand, supported by improved patient selection and increased physician education on dosing and side-effect management, the analysts added. The analysts said that while they remain conservative on Q4 growth, estimating revenue of $109 million, they continue to see longer-term annual sales potential of $700 million. RBC raised its price target on Neurocrine Biosciences to $190 from $187 and kept its outperform rating. Shares of the company were 15% up in the session. Price: 168.02, Change: +22.67, Percent Change: +15.60